Zydus Lifesciences to scale up US specialties business

The company is also looking at an inorganic opportunity over the next two years to have a commercially ready footprint in the US

Allozymes partners with Adisseo on next-gen animal feed production

EMA validates Bristol Myers Squibb’s application for CAR T cell therapy Breyanzi for relapsed or refractory follicular lymphoma

Application based on the Transcend FL trial in which Breyanzi showed deep and durable responses and a consistent and well-established safety profile

Aptar’s nasal unidose system delivers FDA-approved neffy

This marks the first regulatory approval worldwide for nasally-delivered epinephrine

Imfinzi approved in the US for the treatment of resectable non-small cell lung cancer

Based on AEGEAN Phase III trial results which showed Imfinzi-based regimen reduced the risk of recurrence, progression or death by 32% vs. neoadjuvant chemotherapy alone

Glenmark Pharma reports Q1 FY25 consolidated PAT at Rs. 340.2 Cr

India Business grew by 11.9% YoY to Rs. 1196.2 crore

Generative AI is a top driver for cloud investments: Wipro FullStride Cloud Report

Majority of organizations are looking to increase investments in public and hybrid cloud

Evonik expands its formulation capabilities for lipid nanoparticles

Collaboration with KNAUER to streamline and improve the scale-up of LNP formulations

Marksans Pharma Q1 FY25 revenue up 18%

Gross profit was Rs. 328.8 crore, up by 27.8% YoY with a gross margin expansion of 418 bps to 55.7%

Indian API companies to grow by 7-8% and operating profit margin to improve to 12-14% in FY2025: ICRA

Capital expenditure expected to moderate to Rs. 5.6 billion in FY2025 from an estimated Rs. 7.6 billion in FY2024